December 26th, 2011 by Medgadget in News
No Comments »
Abiomed‘s Impella left ventricular assist device, an endovascular percutaneously-delivered LVAD, will soon be getting a more powerful new model. The current model is capable of delivering an augmentation of cardiac output by up to 2.5 liters a minute, but the new Impella cVAD should do around 3.5 L/m, and possibly up to 4 L/m in the not too distant future.
The new device, and above numbers, were announced at Abiomed’s investor day conference and the company hopes to have the device available to clinicians by the Summer of 2012.
Here are the bullet points about Impella cVAD that were provided to us by Abiomed: Read more »
*This blog post was originally published at Medgadget*
November 12th, 2011 by Medgadget in Research
No Comments »
Cost scrutiny and comparative effectiveness research are playing a growing role in shaping healthcare delivery. In light of that, Abiomed Inc. (Danvers, MA) has recently announced the results of a study that showed the company’s Impella heart pump significantly reduced major adverse events at an incremental cost per quality-adjusted life year. “The cost-effective message is directly tied to the financial impact of these better clinical outcomes for patients treated with Impella,” Jeffrey Popma, MD, the director of the angiographic Core Laboratory at Beth Israel Deaconess told Medgadget. Popma was responsible for the planned analysis of the angiographic results.
The device, which the company describes as the “world’s smallest heart pump,” demonstrated an increase in ejection fraction of more than 20% and an improvement in Read more »
*This blog post was originally published at Medgadget*
September 10th, 2011 by Medgadget in Research
No Comments »
Packing hearts on ice destined for transplantation may eventually become a thing of the past. The Organ Care System from TransMedics, which delivers a still-beating heart to a transplant patient, continues to show promise in clinical trials. UCLA recently reported that Rob Evans, a 61-year-old patient suffering from cardiomyopathy, is the most recent recipient of a heart delivered by the device.
We’ve actually covered the Organ Care System (OCS) several times before (we first caught wind of it in 2006). The device, however, is still classified as an investigational device by the FDA; it is undergoing phase II clinical trials in the United States at three sites: the Ronald Reagan UCLA Medical Center, the Cleveland Clinic, and New York-Presbyterian, Columbia University Medical Center.
Check out the UCLA press release explaining the technology and its use in the university’s Heart Transplant Program: Read more »
*This blog post was originally published at Medgadget*
July 27th, 2011 by CodeBlog in Book Reviews, Interviews
2 Comments »
Well, not my heart.
I was contacted awhile ago and asked if I wanted the chance to read and review Tilda Shalof’s new book, Opening My Heart. (Amazon link, but NOT an affiliate link – I live in California and due to a new law, Amazon has cut all ties with us).
I had the chance to include a story in a book that Tilda edited a couple of years ago called Lives in the Balance. So I had fond memories 🙂
I’ll say up front that I enjoyed the book. I had a range of emotions while reading it – frustration, worry, happiness. Frustration because although Tilda is a very experienced ICU nurse, she doesn’t take her own health seriously at all. I read with disbelief as she described her incredible denial of the obvious need to treat the heart condition she was born with.
I was amused at her doctor’s and husband’s reactions when she tried to tell them that if anything went wrong with her surgery, she didn’t want to be kept alive on machines. She explained that she used to have a dog and her husband absolutely refused to euthanize the miserable thing. I liked this passage in particular: “To Ivan, love means never stopping love or giving up. This is what families say. They can’t let go because of love. I hope no one loves me this much, ICU nurses often say to one another.”
Amen, sister.
Tilda writes about Read more »
*This blog post was originally published at code blog - tales of a nurse*
July 21st, 2011 by DrWes in Opinion, Research
No Comments »
To ensure rational and responsible dissemination of this new
technology (transcatheter aortic valve replacement [TAVR]), government,
industry and medicine will need to work in harmony.”
– David R. Holmes, Jr., MD, FACC
President, American College of Cardiology
Today, Edwards Lifesciences’ will request pre-market approval of its SAPIEN Transcatheter Heart Valve from the FDA’s Circulatory Systems Devices Panel of the Medical Devices Advisory Committee. And for the first time, the groundwork for our complicated new era of health care rationing will be exposed.
To win an expensive technology on behalf of patients these days, there will have to be “harmony” between doctors and their professional organizations and government regulators. If not, patients lose.
At issue is a transformative technology – another milestone forwarding medical innovation on behalf of some of our oldest and sickest patients: those with critical aortic stenosis who are too sick to undergo open heart surgery. Aortic stenosis tends to be a disease of the elderly that carries at least a 2-year 50% mortality when accompanied by a weakened heart muscle. Yet thanks to the wonders of careful engineering and some daring researchers that paired their expertise and lessons learned from a variety of disciples (cardiothoracic and peripheral vascular surgery, cardiology, and even cardiac electrophysiology), technigues and technology have combined to offer a percutaneous option for aortic valve replacement.
Everyone involved in this research (and even those who have watched from afar) knows this therapy works. Most believe in the long run, it will prove to be a safer option than open heart surgery in these patients.
But that’s about where the harmony ends. Read more »
*This blog post was originally published at Dr. Wes*
